New drug zigakibart aims to halt kidney damage in IgA nephropathy
NCT ID NCT07146906
First seen Jan 29, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can slow disease progression by reducing harmful deposits in the kidneys. Participants will receive the drug and be monitored for changes in kidney function and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Clinical Trials
RECRUITINGAcworth, Georgia, 30101, United States
Contact Email: •••••@•••••
Contact
-
Colorado Kidney Care Nephrology
RECRUITINGDenver, Colorado, 80230, United States
Contact
Contact Email: •••••@•••••
-
Inter Med Consultants
RECRUITINGEdina, Minnesota, 55435, United States
Contact Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGShanghai, 200025, China
-
Novartis Investigative Site
RECRUITINGKawasaki, Kanagawa, 213-8587, Japan
-
Novartis Investigative Site
RECRUITINGMiyazaki, 889-1692, Japan
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGTaipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.